• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

A Distal Dermatitis

Poll

Can you identify this acral eruption of a week's duration on a 3-year-old boy?

A 3-year-old boy is seen for an acral rash of 7 days’ duration-an eruption of symmetric, flesh-colored monomorphous papules on arms, legs, buttocks, and face. Moderately enlarged, tender cervical lymph nodes are palpated.

What is the most likely diagnosis?

A. Erythema multiforme
B. Lichenoid reaction to medications
C. Non-specific viral exanthema
D. Papular acrodermatitis (Gianotti-Crosti Syndrome)
E. Rocky Moutain Spotted Fever
Related Content
Tapinarof Cream 1.0% Effective for Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock

Tapinarof Cream 1.0% Effective for Atopic Dermatitis: Daily Dose

March 25th 2024
Article

Your daily dose of the clinical news you may have missed.

Tapinarof Cream 1% Effective for Atopic Dermatitis in Person with Skin of Color / image credit diversity: ©marina/stock.adobe.com

Tapinarof Cream 1.0% Effective for Atopic Dermatitis in Persons with Skin of Color: ADORING Phase 3 Program

March 11th 2024
Article

Study participants self-identified as Black, White, or Asian and significant proportions reached improvement of ≥75% in EASI in both in ADORING 1 and ADORING-2.

Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study / image credit ©Brian Jackson/stock.adobe.com

Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study

February 21st 2024
Article

AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.

Tezepelumab Treatment Leads to Sustained Reductions in CSU Disease Activity, Inflammatory Markers / image credit hives; ©chomplearn/stock.adobe.com

Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers

February 21st 2024
Article

AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.

image credit pills money ©alex mlx/stock.adobe.com

Biden Administration Announces First 10 Prescription Drugs Slated for Price Negotiations

August 29th 2023
Article

The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.

Friday's 5 Quotes for Primary Care: 3-24-2023

Friday's 5 Quotes for Primary Care: 3-24-2023

March 24th 2023
Article

Statin-eligible patients in minority groups significantly undertreated; metabolically healthy obesity on the rise; menstruation irregularities suggest later CVD risk; and 2 more studies of note.

© 2024 MJH Life Sciences

All rights reserved.